Abstract 110P
Background
The CAPSTONE-1 study established adebrelimab combined with carboplatin and etoposide as the first-line standard of care for patients with extensive-stage small-cell lung cancer (ES-SCLC) in China; however, the clinical outcomes of adebrelimab in routine practice remain largely unknown, particularly among patients with brain metastases. Here, we present the first evaluation of the safety and effectiveness of adebrelimab for the first-line treatment of ES-SCLC in a real-world setting.
Methods
In this prospective, multicenter, observational study in China, patients with ES-SCLC who were scheduled to receive adebrelimab-based first-line treatment at the discretion of the investigator were included. The primary outcome was safety profiles according to CTCAE version 5.0. Secondary outcomes included objective response rate (ORR), disease control rate (DCR), duration of response, progression-free survival (PFS), and overall survival (OS).
Results
Between March 9, 2023 and May 7, 2024, 188 patients were included (median age 64 years [range 41-85], 158 [84%] males, 65 [34.6%] current smokers, 42 [22.3%] with brain metastases, 52 [27.7%] with liver metastases, and 79 [42.0%] with pleural effusion). As of August 21, 2024, the median follow-up duration was 5.6 months (IQR 4.1-7.8). Among the 188 patients, the real-world ORR was 65.4% (95% CI 58.2-72.2, and the real-world DCR was 85.1% (95% CI 79.2-89.9). Median PFS was 6.9 months (95% CI 5.8-7.2), with a 6-month PFS rate of 56.9% (95% CI 48.0-64.9). Median PFS was 5.4 months (95% CI 4.8-7.5) in patients with brain metastases and 7.0 months (95% CI 5.9-7.6) in those without brain metastases, without statistical difference (P=0.110). OS data are not mature yet. Treatment-emergent adverse events (TEAEs) of any grade were reported in 166 (88.3%) patients, and grade 3 or worse TEAEs occurred in 60 (31.9%) patients.
Conclusions
This real-world study enrolled a broader and more diverse SCLC patient population compared to the CAPSTONE-1 trial. Despite this, adebrelimab-based regimen showed favorable effectiveness and a manageable safety profile in the first-line setting for ES-SCLC, offering additional pivotal data to the CAPSTONE-1 trial.
Legal entity responsible for the study
The authors.
Funding
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - Anti-CTLA4 therapy leads to early expansion of peripheral Th17 population and induction of Th1 cytokines
Presenter: Mari Nakazawa
Session: Poster Display session
Resources:
Abstract
196P - Single-cell analysis of stage-I high-grade serous ovarian carcinoma reveals the essential role of regulatory T cells in early tumor establishment
Presenter: Joanna Mikulak
Session: Poster Display session
Resources:
Abstract
197P - Comprehensive immunoprofiling of the intratumoral and peripheral T cell receptor gene repertoire in triple-negative breast cancer patients
Presenter: Antonios Mingos
Session: Poster Display session
Resources:
Abstract
198P - Association of types of treatment modalities with expression of T Lymphocytes (CD4, CD8, Treg) in breast cancer patients and their clinical outcome
Presenter: Arshi Rizwan
Session: Poster Display session
Resources:
Abstract
199P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Poster Display session
Resources:
Abstract
200P - CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant NSCLC
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
201P - Underlying mechanisms of neutrophil-mediated immunosuppression and resistance to treatment in breast cancer: Further evidence that these cells matter
Presenter: Bruna Filipa Correia
Session: Poster Display session
Resources:
Abstract
202P - Mining tumor infiltrating B cells to discover antibody-target pairs and develop novel therapies
Presenter: Matthieu Delince
Session: Poster Display session
Resources:
Abstract
203P - Targeting IL-33 reprograms tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
Presenter: Xuyao Zhang
Session: Poster Display session
Resources:
Abstract
204P - Deciphering the crosstalk between tumor and circulating immune microenvironment in advanced NSCLC patients undergoing immunotherapy
Presenter: Prisca Tamarozzi
Session: Poster Display session
Resources:
Abstract